Roche announced new data from its Alzheimer’s disease programs is presented at the Alzheimer’s Association International Conference (AAIC) in Toronto, Canada (July 27–30). The data highlight Roche’s comprehensive approach to tackling Alzheimer’s—from early detection to treatment—across both its diagnostics and pharmaceutical pipelines.

Key oral presentations include new results from the ongoing Phase Ib/IIa Brainshuttle AD study, which continue to show fast and significant reductions in brain amyloid plaques. Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease, with both studies set to begin later this year.

“Alzheimer’s is one of the most difficult healthcare challenges today, and addressing it means acting early and treating effectively,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development at Roche. “Trontinemab is designed to more effectively reach and target disease mechanisms in the brain. By combining new treatment strategies with advanced diagnostics, we’re aiming to intervene earlier and more effectively. These Phase III programs reflect our commitment to changing the course of this devastating disease.”

Roche also presented new data on the Elecsys pTau217 blood test, which performs similarly to PET scans and cerebrospinal fluid (CSF) tests in identifying amyloid pathology—a hallmark of Alzheimer’s. The Elecsys test, which received Breakthrough Device Designation from the U.S. FDA, will also be used to support participant selection in the TRONTIER trials.

“Blood-based tests for Alzheimer’s could significantly improve access and speed up diagnosis,” said Matt Sause, CEO of Roche Diagnostics. “Our Elecsys pTau217 test offers similar accuracy to PET imaging but with just a simple blood draw—making it practical for routine clinical use and easier for patients and families.”

Globally, up to 75% of people with Alzheimer’s symptoms are undiagnosed, and those who are often wait an average of 2.8 years to receive a diagnosis. Many still go untreated.